Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 17;93(8):E202-E205.
doi: 10.1002/ajh.25146. Online ahead of print.

Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia

Brenda Chyla  1 , Naval Daver  2 , Kelly Doyle  1 , Evelyn McKeegan  1 , Xin Huang  1 , Vivian Ruvolo  2 , Zixing Wang  2 , Ken Chen  2 , Andrew Souers  1 , Joel Leverson  1 , Jalaja Potluri  1 , Erwin Boghaert  1 , Anahita Bhathena  1 , Marina Konopleva  2 , Relja Popovic  1
Affiliations

Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia

Brenda Chyla et al. Am J Hematol. .
No abstract available

Keywords: AML; BLC-2; Venetoclax.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mutations affecting response to venetoclax in AML. A, Mutations observed pre‐therapy and end of treatment with single agent venetoclax therapy. Yellow indicates IDH or SRSF2 mutations; orange indicates ZRSR2 mutations; blue indicates FLT3‐ITD or PTPN11 mutations; purple indicates newly detected FLT3‐ITD or PTPN11 mutations; blank cells indicate specific mutation was not detected, †Biological activity defined as any reduction in BM blast count while on venetoclax therapy; B, Time on study for patients with mutations associated with intrinsic sensitivity (pre‐therapy IDH/spliceosome mutants) and intrinsic resistance (pre‐therapy FLT3‐ITD/PTPN11 mutants) to venetoclax; C, Time on study for patients with mutations associated with intrinsic sensitivity, intrinsic resistance, and acquisition of mutations associated with acquired resistance (FLT3‐ITD/PTPN11 mutants) to venetoclax; D, Tumor growth inhibition by venetoclax plus quizartinib in mice xenografted with FLT3‐ITD+ MV‐4–11 cells
See this image and copyright information in PMC

References

    1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. - PMC - PubMed
    1. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. - PMC - PubMed
    1. Mali RS, Laseter EA, Doyle K, et al. FLT3‐ITD activation mediates resistance to the BCL‐2 selective antagonist, venetoclax, in FLT3‐ITD mutant AML models. Blood. 2017;130:1348.
    1. Chan SM, Thomas D, Corces‐Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL‐2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. - PMC - PubMed
    1. Yoshimi A, Lin KT, Wiseman D, et al. Spliceosomal dysfunction is a critical mediator of IDH2 mutant leukemogenesis. Blood. 2017;130:473.